Figure 6.

Ankylosing spondylitis: disease activity. Infliximab rapidly reduces disease activity compared with placebo (n = 70 patients). Percentage of patients with improvement ≥50% in the Bath Ankylosing Spondylitis Disease Activity Index. P <0.0001 from 2 weeks onwards. Modified with permission from [71].

Smolen and Emery Arthritis Research & Therapy 2011 13(Suppl 1):S2   doi:10.1186/1478-6354-13-S1-S2